Showing 5611-5620 of 8159 results for "".
- Zein Obagi, MD To Direct 24th Ultimate Skin Health Symposiumhttps://practicaldermatology.com/news/20120807-zein_obagi_md_to_direct_24th_ultimate_skin_health_symposium/2459755/Zein E. Obagi, MD was named director of the 24th Ultimate Skin Health Symposium, a three-day skin rejuvenation program taking place at the Montage Hotel, Beverly Hills, CA, from November 9-11, 2012. Key topics of the symposium will i
- DASIL Announces Inaugural Congresshttps://practicaldermatology.com/news/20120725-dasil_announces_inaugural_congress/2459763/The Dermatologic & Aesthetic Surgery International League (DASIL), headquartered in Chicago, Illinois, is hosting its first annual DASIL Congress, to be held on the island of Malta, from October 31 to November 4, 2012. This international dermatol
- Provectus Pharmaceuticals Presents Phase II Data on PV-10https://practicaldermatology.com/news/20120627-provectus_pharmaceuticals_presents_phase_ii_data_on_pv-10/2459780/Provectus Pharmaceuticals, Inc. (OTCBB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, presented its top-line final data from the Phase II clinical trial of PV-10 for metastatic melanoma. Results were showcased at the
- Data Support Vismodegib for Metastatic, Locally Advanced BCChttps://practicaldermatology.com/news/20120613-data_support_vismodegib_for_metastatic_locally-advanced_bcc/2459783/New data demonstrate the anti-tumor activity of vismodegib (Erivedge, Genentech) 150mg daily in metastatic and locally advanced basal cell carcinoma (BCC). (N Engl J Med; 366:2171-2179) The study found that the independently assessed response rate was 30 percent in patients with metastatic BCC (n=33
- Merz Appoints New Vice President of Medical Dermatologyhttps://practicaldermatology.com/news/20120611-merz_appoints_new_vice_president_of_medical_dermatology/2459786/Merz, Inc. has appointed James P. Hartman as Vice President of Medical Dermatology. In the new role, Hartman will be responsible for the company's Medical and OTC/OTX dermatology business unit, which includes Naftin® (naftifine hydrochloride) and Mede
- Dermatologists Can Spot Early Psoriatic Arthritishttps://practicaldermatology.com/news/20120521-dermatologists_can_spot_early_psoriatic_arthritis/2459795/Clinical dermatologists could help diagnose early psoriatic arthritis (EPsA) through the use of patient questioning and subsequent imaging studies in collaboration with rheumatologists and radiologists, data suggest. (
- Study: FDA Approves Drugs Faster than Europe, Canadahttps://practicaldermatology.com/news/20120517-study_fda_approves_drugs_faster_than_europe_canada/2459797/Drugs are approved faster in the US than in Europe and Canada, new research from Yale University School of Medicine shows. Authors of the study, published in The New England Journal of Medicine, reviewed decisions from 2001 to 2010 by the FDA and regulators in Canada and Europe, Health Canada and th
- FDA Extends Deadline for Sunscreen Label Compliancehttps://practicaldermatology.com/news/20120514-fda_extends_deadline_for_sunscreen_compliance/2459802/Sunscreen manufacturers have won a small victory from the Food and Drug Administration (FDA), which has extended the deadline for compliance with new labeling back to December 2013 for some companies. The industry pushed back on the agency, which ordered changes to sunscreens last summer with an ori
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.